Cargando…

Mechanistic understanding of human SLFN11

Schlafen 11 (SLFN11) is an interferon-inducible antiviral restriction factor with tRNA endoribonuclease and DNA binding functions. It is recruited to stalled replication forks in response to replication stress and inhibits replication of certain viruses such as the human immunodeficiency virus 1 (HI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metzner, Felix J., Wenzl, Simon J., Kugler, Michael, Krebs, Stefan, Hopfner, Karl-Peter, Lammens, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482658/ https://www.ncbi.nlm.nih.gov/pubmed/36115853 http://dx.doi.org/10.1038/s41467-022-33123-0

Ejemplares similares

Structural and biochemical characterization of human Schlafen 5
por: Metzner, Felix J, et al.
Publicado: (2022)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

ATP driven structural changes of the bacterial Mre11:Rad50 catalytic head complex
por: Möckel, Carolin, et al.
Publicado: (2012)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
por: Coleman, Niamh, et al.
Publicado: (2020)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
por: Willis, Sophie E., et al.
Publicado: (2021)

The bacterial Mre11–Rad50 homolog SbcCD cleaves opposing strands of DNA by two chemically distinct nuclease reactions
por: Saathoff, Jan-Hinnerk, et al.
Publicado: (2018)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Mechanistic insight into the assembly of the HerA–NurA helicase–nuclease DNA end resection complex
por: Ahdash, Zainab, et al.
Publicado: (2017)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
por: Nogales, Vanesa, et al.
Publicado: (2015)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
por: Mezzadra, Riccardo, et al.
Publicado: (2019)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
por: Moribe, Fumiya, et al.
Publicado: (2021)

Crystal Structure of Human TWEAK in Complex with the Fab Fragment of a Neutralizing Antibody Reveals Insights into Receptor Binding
por: Lammens, Alfred, et al.
Publicado: (2013)

DNA damage-Induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
por: Li, Manqing, et al.
Publicado: (2018)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin
por: Peng, Yaojun, et al.
Publicado: (2019)

Study of Clinical Predictive Value and Immune Characterization of SLFN11 in Clear Cell Renal Cell Carcinoma
por: Liu, Yifu, et al.
Publicado: (2021)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

Ice thickness monitoring for cryo-EM grids by interferometry imaging
por: Hohle, Markus Matthias, et al.
Publicado: (2022)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex
por: Nightingale, Katie, et al.
Publicado: (2022)

A Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence
por: Berger, Michael, et al.
Publicado: (2010)

SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway
por: Zhou, Chenhao, et al.
Publicado: (2020)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA
por: Pippig, Diana A., et al.
Publicado: (2009)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Human SLFN5 and its Xenopus Laevis ortholog regulate entry into mitosis and oocyte meiotic resumption
por: Vit, Gianmatteo, et al.
Publicado: (2022)

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
por: Kundu, Kiran, et al.
Publicado: (2021)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Role of the novel endoribonuclease SLFN14 and its disease-causing mutations in ribosomal degradation
por: Fletcher, Sarah J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8c3snla8m6cku2fc64vgdt1a2b